bioRxivMicrobiologyPreprint
Identification, Characterization and Synthesis of Natural Parasitic Cysteine Protease Inhibitors -- More Potent Falcitidin Analogs
S. Brinkmann, S. Semmler, C. Kersten, M. A. Patras, M. Kurz, N. Fuchs, S. J. Hammerschmidt, J. Legac, P. E. Hammann, A. Vilcinskas, P. J. Rosenthal, T. Schirmeister, A. Bauer, T. F. Schaeberle
Abstract
Protease inhibitors represent a promising therapeutic option for the treatment of parasitic diseases such as malaria and human African trypanosomiasis. Falcitidin was the first member of a new class of inhibitors of falcipain-2, a cysteine protease of the malaria parasite Plasmodium falciparum. Using a metabolomics dataset of 25 Chitinophaga strains for molecular networking enabled identification of over 30 natural analogs of falcitidin. Based on MS/MS spectra, they vary in their amino acid chain length, sequence, acyl residue, and C-terminal functionalization; therefore, they were grouped into the four falcitidin peptide families A-D. The isolation, characterization and absolute structure elucidation of two falcitidin-related pentapeptide aldehyde analogs by extensive MS/MS spectrometry and NMR spectroscopy in combination with advanced Marfeys analysis was in agreement with the in silico analysis of the corresponding biosynthetic gene cluster. Total synthesis of chosen pentapeptide analogs followed by in vitro testing against a panel of proteases revealed selective parasitic cysteine protease inhibition and additionally low-micromolar inhibition of -chymotrypsin. The pentapeptides investigated here showed superior inhibitory activity compared to falcitidin.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Comparing sequence and structure of falcipains and human homologs at prodomain and catalytic active site for malarial peptide-based inhibitor design
Thommas Mutemi Musyoka, Joyce Njoki Njuguna, Özlem Taştan Bishop·Malaria JournalPeer-reviewed·May 3, 2019
- Covalent macrocyclic proteasome inhibitors mitigate resistance in Plasmodium falciparum
J. M. Bennett, K. E. Ward, … M. Bogyo·bioRxiv·Jul 3, 2023
- Identification of an inhibitory pocket in falcilysin provides a new avenue for malaria drug development
G. Wirjanata, J. Lin, … Z. Bozdech·bioRxiv·Apr 8, 2021
- Mapping the S1 and S1 subsites of cysteine proteases with new dipeptidyl nitrile inhibitors as trypanocidal agents
L. Cianni, C. Lemke, … C. A. Montanari·bioRxiv·Sep 8, 2019
- Characterization of P. falciparum dipeptidyl aminopeptidase 3 specificity reveals structural factors responsible for differences in amino acid preferences between peptide-based substrates and covalent inhibitors.
Laura E. de Vries, Mateo I. Sanchez, … Edgar Deu·bioRxiv·Aug 10, 2018
- Novel inhibitors designing against the potential drug target of Plasmodium falciparum M17 Leucyl Aminopeptidase - PfM17LAP
Govinda Rao Dabburu, Manish Kumar, Naidu Subbarao·bioRxiv·Dec 14, 2021